$ABVC 8-K/A SEC Filings

On August 3, 2026, ABVC BioPharma, Inc. (the “Company”) determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. (the “Distribution”), which had been scheduled to occur on August 3, 2026. T...

We previously reported that between April 11, 2025, and May 27, 2025, the Company sold an aggregate of 1,987,557 shares (the “Shares”) of its Common Stock to 43 Non-U.S. Persons (as defined in Regulation S under the Securities Act). The ...

We filed a Current Report on Form 8-K on October 18, 2024, to disclose that on October 10, 2024, WWC, P.C. (“WWC”), serving as the Company’s independent registered public accounting firm, agreed not to renew its engagement with the Compa...

This Definitive Agreement (“Agreement”) is entered into as of July 15, 2025, by and between ABVC BioPharma, Inc. (“ABVC”), and Shuling Jiang (hereinafter referred to as “Shuling”).

We previously reported that between April 30, 2025 and May 9, 2025, the Company sold an aggregate of 1,030,413 shares (the “Shares”) of its Common Stock to 22 Non-U.S. Persons (as defined in Regulation S under the Securities Act. The off...

On April 30, 2025, we reported that the Company sold an aggregate of an aggregate of 724,372 shares (the “Shares”) of its Common Stock to 15 Non-U.S. Persons (as defined in Regulation S under the Securities Act. The offer and sale of the...

Silicon Valley, CA – May 14, 2025 – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications...

On April 30, 2025, the Company reported that it received a letter from the listing qualifications staff (the “Staff”) of Nasdaq informing it that, as reported in its Annual Report on Form 10-K for the year ended December 31, 2024, becaus...

On April 15, 2024, 2025, ABVC BioPharma, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) reporting, among other things, that because the Company’s financial statements for the fiscal year ended December 31, 2...

Silicon Valley, CA (April 16, 2025) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, leveraging it...

Fremont, CA (January 13, 2025) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is pleased to anno...

This Amendment Agreement (the “Amendment”) is made and entered into as of June 23, 2024, by and between AiBtl BioPharma Inc., a Delaware State corporation, and BioLite, Inc., a Taiwan corporation.

This Amendment Agreement (the “Amendment”) is made and entered into as of June 18, 2024, by and between ForSeeCon Eye Corporation, a British Virgin Islands corporation, and BioFirst Corporation, a Taiwan corporation.

This Amendment No. 2 to Senior Convertible Promissory Note (this “Amendment”) is entered into as of February [ ], 2024 (the “Amendment Date”), by and between Lind Global fund II LP, a Delaware limited partnership (“Holder”), and ABVC Bio...

This Amendment No. 1 to Senior Convertible Promissory Note (this “Amendment”) is entered into as of February [ ], 2024 (the “Amendment Date”), by and between Lind Global fund II LP, a Delaware limited partnership (“Holder”), and ABVC Bio...

On November 12, 2023, the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AIBL”, or the acquired company) for the Company and BioLite’s...

This Amendment No. 1 to Senior Convertible Promissory Note (this “Amendment”) is entered into as of January 12, 2024, by and between Lind Global fund II LP, a Delaware limited partnership (“Lender”), and ABVC BioPharma, Inc., a Nevada co...

This Amendment No. 1 (the “Amendment”) to cooperation agreement (the “Original Agreement”, the transaction contemplated herein the “Transaction”) is entered into as of August 28, 2023, by and between ABVC BioPharma, Inc. (“ABVC” or the “...

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement